Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VericelVCEL +1.08%83 Operating Cash Flow per Share is $1.32 as of Jun. 2026. GuruFocus rates VCEL with a GF Score™ of 83/100 and a GF Value™ of $54.79 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,130 Biotechnology companies, Vericel ranks better than 74.69% on this metric.
Vericel's operating cash flow per share for the
three
months ended in Jun. 2026 was $0.31.
Vericel's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $1.32.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Vericel was 51.80% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 38.40% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 23.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Vericel's Operating Cash Flow per Share or its related term are showing as below:
VCEL'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -8.6 Med: 20.5 Max: 73.9
Current: 38.4
During the past 13 years, Vericel's highest 3-Year average Operating Cash Flow per Share Growth Rate was 73.90% per year. The lowest was -8.60% per year. And the median was 20.50% per year.
VCEL's 3-Year OCF Growth Rate is ranked better than 74.69% of 1130
companies
in the Biotechnology industry
Industry Median: 16.85
vs VCEL: 38.40
Vericel Operating Cash Flow per Share Related Terms
Vericel Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Vericel's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VCEL vs ADMA, KLRA, COAG: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Vericel's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vericel Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vericel's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Vericel's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.32
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $1.32 mean?
Vericel (VCEL) has a Operating Cash Flow per Share of $1.32 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Vericel and its competitors. According to the industry distribution chart, Vericel ranks #286 out of 1130 companies in the Biotechnology industry, placing it in the top 25.3%.
Is Vericel's Operating Cash Flow per Share too high?
Vericel's current Operating Cash Flow per Share is $1.32. The Biotechnology industry median Operating Cash Flow per Share is 16.85. Vericel's value of $1.32 is 92.2% below this industry median. Based on the distribution chart, Vericel ranks #286 out of 1130 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vericel has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's Operating Cash Flow per Share compare to ADMA and KLRA?
According to the Biotechnology industry distribution chart, Vericel ranks #286 out of 1130 companies for Operating Cash Flow per Share. This puts Vericel in the upper half of its industry. The industry median Operating Cash Flow per Share is 16.85. Vericel's value of $1.32 is 92.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 16.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vericel's current Operating Cash Flow per Share of $1.32 is 92.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Vericel and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 16.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vericel's current Operating Cash Flow per Share is $1.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (VCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $54.79, compared to a current price of $40.21 — trading 26.6% below its estimated fair value. The current Operating Cash Flow per Share is $1.32 and 92.2% below the Biotechnology industry median of 16.85. Vericel's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Vericel (VCEL), the current Operating Cash Flow per Share is $1.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (VCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of $40.21 is trading 26.6% below its estimated GF Value™ of $54.79.
GuruFocus considers Vericel to be Modestly Undervalued.
Key valuation signals for VCEL:
Operating Cash Flow per Share: $1.32
GF Value™: $54.79 vs. price of $40.21 (26.6% below fair value)
Industry Position: 92.2% below the Biotechnology median (#286 of 1130)
No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
83GF Score
Get the complete analysis for VCEL
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCEL has been successfully added to your 
